Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

PURPOSE: To identify prognostic factors associated with survival beyond 4 years and overall response in patients with metastatic melanoma treated with high-dose bolus i.v. interleukin-2 (IL-2) given either alone or in combination with a variety of melanoma vaccines. STUDY DESIGN: 684 consecutive pat...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Smith, Franz O., Downey, Stephanie G., Klapper, Jacob A., Yang, James C., Sherry, Richard M., Royal, Richard E., Kammula, Udai S., Hughes, Marybeth S., Restifo, Nicholas P., Levy, Catherine L., White, Donald E., Steinberg, Seth M., Rosenberg, Steven A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2008
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2656367/
https://ncbi.nlm.nih.gov/pubmed/18765555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0116
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky